| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a1918a729d3e9d8ecb68e96cfa1f31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d488dc94c49979bd21188937c42d77b4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2008-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3e82aa20aa4a4ef24ec8b743b9fa389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_059c8c2fc938a4f952b8dedd95646757 |
| publicationDate |
2010-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2466025-A |
| titleOfInvention |
C3/ITGAM polymorphisms and cancer prognosis |
| abstract |
The invention provides methods to determine the cancer prognosis of subjects and to adapt the treatment protocol of subjects having or susceptible to cancer. The method comprises steps of determining in vitro the genotype of a subject at a polymorphism in the C3-ITGAM (integrin alpha M) axis, making a cancer prognosis of the subject based on said genotype and selecting an anti-cancer treatment for the subject. ITGAM (or CD 11b) may have a polymorphism at position 425 in the domain containing Asp398 to Thr451, and the C3 (complement component 3) may have a polymorphism at position 80. A therapeutic antibody (rituximab) may then be administered accordingly. Determining the polymorphisms may utilise RNA hybridisation, a specific affinity reagent, enzyme digestion or PCR amplification. Specifically the cancer may be non-Hodgkin's lymphoma. Methods of treatment are also provided. |
| priorityDate |
2008-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |